

# STOCHASTIC SURVIVAL ANALYSIS OF AN EPIDEMIC MODEL WITH INNATE IMMUNITY AND TREATMENT\*

Lijun Chen <sup>1</sup>, Wenshuang Li <sup>2</sup>, Ruiyang Zhou <sup>2,3</sup>, Fengying Wei <sup>2,4,†</sup>

**Abstract** The innate immunity helps the individuals in the exposed compartment return into the ones in the susceptible compartment when a pathogen or virus invades the local population of having four compartments: the susceptible, the exposed, the infected and the recovered. In this study, we propose a stochastic SEIR model with innate immunity and treatment. Here, Holling type II functional responses are used to describe the saturated effects of the innate immunity and treatment. Then, we obtain the extinction of the exposed and the infected when the basic reproduction number  $\mathcal{R}_0 < 1$  and the exponential decline rate  $\nu < 0$  are valid. Moreover, we conclude that when innate immunity and treatment increase, the time that the exposed and the infected approach zero reduces. We also find that the deterministic SEIR model reaches extinction a bit faster than stochastic SEIR model. Further, the persistence in the mean and stationary distribution to stochastic SEIR model are obtained under suitable conditions. Finally, the numerical investigations with two methods and a case study of Fuzhou COVID-19 epidemic of 2022 are discussed.

**Keywords** SEIR epidemic model, Holling type II functional response, Innate immunity, Extinction and persistence, COVID-19

**MSC(2010)** 60H10, 92B05, 92D30.

## 1. Model formulation

The reliable mathematical epidemic models were proposed to predict and control the spread of infectious diseases since the pioneering work was discussed by Kermack and McKendrick in [1]. Later, some compartment models were extensively studied

<sup>†</sup>The corresponding author. Email: [weifengying@fzu.edu.cn](mailto:weifengying@fzu.edu.cn) (F. Wei)

<sup>1</sup>Jin Shan College, Fujian Agriculture and Forestry University, Fuzhou 350000, China

<sup>2</sup>School of Mathematics and Statistics, Fuzhou University, Fuzhou 350116, China

<sup>3</sup>Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Sichuan 61173, China

<sup>4</sup>Center for Applied Mathematics of Fujian Province, Fuzhou University, Fuzhou 350116, China

\*The authors were supported by the Natural Science Foundation of Fujian Province of China (2021J01621), Special Projects of the Central Government Guiding Local Science and Technology Development (2021L3018), the Science and Technology Project for Young Teachers of Jin Shan College of Fujian Agriculture and Forestry University (KX230301), the Science and Technology Project of Education Department of Fujian Province of China (JAT210662).

in the recent contributions [2–14]. The research results showed that the transmission mechanisms of infectious diseases played very important role when establishing the mathematical models. Especially, the incidence rates between the susceptible and the infected quantitatively were governed to describe the transmission mechanisms of infectious diseases, **such as the bilinear incidence rate, the standard incidence rate, the Beddington-DeAngelis incidence rate, and the generalized nonlinear incidence rate etc in [1, 5, 9, 15–24, 26–28].**

The innate immunity, one of main defense mechanisms formed by organisms in the process of long-term evolution, is extensively discussed on cellular level in recent studies [29–37]. Usually, the innate immunity of the individuals plays crucial roles because the responses of innate immunity work immediately or within hours after pathogens or virus invade the hosts. Meanwhile, the innate immunity of different individuals presents distinct timelines after they are invaded by pathogens or viruses. However, from the best knowledge of the authors, the studies of innate immunity on population level are few for epidemic models. For instance, **the effects of immunity are considered in an impulsive stochastic model, in which the authors of [25] mainly studied the saturated tumor-immune responses.** And the nonlinear innate immunity and saturated treatment in the forms of Holling type II are governed for an SEIS epidemic model (1.3) in [26], in which the authors of [26] further compare the dynamics of model (5.1) with linear innate immunity and linear treatment. In this study, we believe that the role of innate immunity is of importance for epidemic models, we further are motivated by recent contributions to establish an SEIR model with nonlinear innate immunity and nonlinear treatment.

The aforementioned innate immunity helps the exposed getting recovery and returning into the susceptible again, despite the impacts of innate immunity are limited to the exposed. In this study, we use Holling type II functional response  $g(E) = aE/(1 + kE)$  with  $a > 0, k \geq 0$  to describe the increasing tendency of the impacts of innate immunity, where  $1/a$  is the average returning period that the exposed remove from the exposed compartment and return into the susceptible compartment due to the existence of innate immunity;  **$k$  is a non-negative constant measuring the limitation in innate immunity;**  $1/(1 + kE)$  declines the exposed returning into the susceptible compartment due to low immunoglobulins and neutrophil deficiency as studied in [22, 23]. Meanwhile, the treatment of the infected is an effective and important measure for controlling infectious diseases. We assume that the infected return into the susceptible compartment due to the temporary immunity after they receive the treatment in medical agents, by governing Holling type II functional response  $h(I) = \gamma I/(1 + bI)$  with  $\gamma > 0, b \geq 0$ . Here,  $1/\gamma$  is the average loss period of temporary immunity that the infected lose their temporary immunity after they receive the treatment and return into the susceptible compartment;  **$b$  is a non-negative constant measuring the limitation in treatment availability;**  $1/(1 + bI)$  prevents the infected returning into the susceptible compartment due to the limited medical resources. When  $b = 0$ ,  $h(I)$  degenerates the linear forms in [10, 11]. Moreover, some infected individuals get the lifelong immunity after they receive the treatment and return into the recovered compartment with the recovery rate  $\mu$ . Thus, we derive the following model:

$$\dot{S}(t) = \Gamma - \delta S - \frac{\beta SI}{\phi(I)} + \frac{aE}{1 + kE} + \frac{\gamma I}{1 + bI},$$

$$\begin{aligned}
\dot{E}(t) &= \frac{\beta SI}{\phi(I)} - (\delta + \sigma)E - \frac{aE}{1 + kE}, \\
\dot{I}(t) &= \sigma E - (\delta + \mu)I - \frac{\gamma I}{1 + bI}, \\
\dot{R}(t) &= \mu I - \delta R.
\end{aligned} \tag{1.1}$$

In the model (1.1),  $\Gamma$  is the constant recruitment rate,  $\delta$  denotes the natural death rate of the total population,  $\beta$  is the contact rate between the susceptible and the infected,  $\phi(I)$  is an increasing function with the properties that  $\phi(0) = 1$  and  $\phi'(I) \geq 0$ ,  $\sigma$  represents the positive infection rate from the exposed to the infected. We derive that  $\dot{N}(t) = \dot{S}(t) + \dot{E}(t) + \dot{I}(t) + \dot{R}(t) = \Gamma - \delta N(t)$ , here  $N(0) = S(0) + E(0) + I(0) + R(0) \geq 0$ . Then, it follows that  $\limsup_{t \rightarrow \infty} N(t) < \frac{\Gamma}{\delta}$ . Therefore, we derive a positive invariant set  $\Omega = \{(S, E, I, R) \in \mathbb{R}_+^4 : N(t) < \frac{\Gamma}{\delta}\}$ . The disease-free equilibrium point of model (1.1) is denoted by  $P_0(\frac{\Gamma}{\delta}, 0, 0, 0)$ . By the next generation matrix method in [38, 39], the matrices  $F$  and  $V^{-1}$  are respectively written as

$$F = \begin{pmatrix} 0 & \frac{\beta\Gamma}{\delta} \\ 0 & 0 \end{pmatrix}, \quad V^{-1} = \frac{1}{(\delta + \sigma + a)(\delta + \mu + \gamma)} \begin{pmatrix} \delta + \mu + \gamma & 0 \\ \sigma & \delta + \sigma + a \end{pmatrix}.$$

By Theorem 2 in [40], the basic reproduction number of model (1.1) is

$$\mathcal{R}_0 = \rho(FV^{-1}) = \frac{\Gamma\beta\sigma}{\delta(\delta + \sigma + a)(\delta + \mu + \gamma)}. \tag{1.2}$$

In fact, the endemic equilibrium point  $P^*(S^*, E^*, I^*, R^*)$  of (1.1) is calculated as follows:

$$\begin{aligned}
S^* &= \frac{1}{\beta} (b\delta I^* + \mu b I^* + \mu + \gamma + \delta) \phi(I^*) \\
&\quad \times \left( \frac{\delta + \sigma}{b\sigma I^* + \sigma} + \frac{a}{kI^*(b\delta I^* + \gamma + \delta) + \mu k I^*(bI^* + 1) + \sigma + b\sigma I^*} \right), \\
E^* &= \frac{b(\delta + \mu)(I^*)^2 + (\delta + \mu + \gamma)I^*}{\sigma(1 + bI^*)}, \quad R^* = \frac{\mu I^*}{\delta},
\end{aligned}$$

and  $I^*$  is the solution of  $A_5\phi(I^*) + A_4(I^*)^4 + A_3(I^*)^3 + A_2(I^*)^2 + A_1(I^*) + A_0 = 0$ , where

$$\begin{aligned}
A_5 &= -\delta k b^2 (\delta + \sigma)(\delta + \mu)^2 - \delta b (\delta + \mu)(\delta + \sigma)(k\gamma + k\delta + k\mu + b\sigma) \\
&\quad - \delta \sigma b (\delta + \sigma)(\delta + \mu) - k b \delta (\delta + \sigma)(\delta + \mu)(\mu + \gamma + \delta) - a \delta \sigma b^2 (\delta + \mu) \\
&\quad - \delta (\delta + \sigma)(\mu + \gamma + \delta)(k\gamma + k\delta + k\mu + b\sigma) - a b \delta \sigma (2\mu + \gamma + 2\delta) \\
&\quad - \delta \sigma (\delta + \sigma)(\mu + \gamma + \delta) - a \delta \sigma (\mu + \gamma + \delta), \\
A_4 &= \beta b^2 k (\delta + \sigma)(\delta + \mu)^2, \\
A_3 &= \Gamma \beta \sigma b^2 k (\delta + \mu) - \beta (\delta + \sigma)(\mu + \gamma + \delta)(k\gamma + k\delta + k\mu + b\sigma) \\
&\quad - \beta k b (\delta + \sigma)(\delta + \mu)(\mu + \gamma + \delta) + \beta \sigma \gamma k b (\delta + \mu),
\end{aligned}$$

$$\begin{aligned}
A_2 &= \Gamma\beta\sigma b(k\gamma + k\delta + k\mu + b\sigma) + \Gamma\beta\sigma kb(\delta + \mu) - \beta\sigma b(\delta + \sigma)(\delta + \mu) \\
&\quad - \beta(\delta + \sigma)(\mu + \gamma + \delta)(k\gamma + k\delta + k\mu + b\sigma) + \beta\sigma\gamma(k\gamma + k\delta + k\mu + b\sigma), \\
A_1 &= \Gamma\beta\sigma(k\gamma + k\delta + k\mu + b\sigma) + \Gamma\beta\sigma^2 b - \beta\sigma(\delta + \sigma)(\mu + \gamma + \delta) + \beta\sigma^2\gamma, \\
A_0 &= \Gamma\beta\sigma^2.
\end{aligned}$$

In the real circumstances, the existences of environmental fluctuations and population mobility lead to the variations on persistence and extinction of epidemic models in [4–10, 20, 27, 28, 41–43]. Therefore, it is necessary to introduce the environmental fluctuations into model (1.1). The independent environmental fluctuations are proportional to  $S$ ,  $E$ ,  $I$  and  $R$  of model (1.1), which are provided by multiplicative white noises. More precisely, we consider a Markov process  $X(t) = (S(t), E(t), I(t), R(t))^T$  when  $\Delta t \rightarrow 0$ , and we derive the following descriptions:

$$\begin{aligned}
\mathbb{E}[S(t + \Delta t) - S(t)|X_t = x] &\approx \left( \Gamma - \delta S - \frac{\beta SI}{\phi(I)} + \frac{aE}{1 + kE} + \frac{\gamma I}{1 + bI} \right) \Delta t, \\
\mathbb{E}[E(t + \Delta t) - E(t)|X_t = x] &\approx \left( \frac{\beta SI}{\phi(I)} - (\delta + \sigma)E - \frac{aE}{1 + kE} \right) \Delta t, \\
\mathbb{E}[I(t + \Delta t) - I(t)|X_t = x] &\approx \left( \sigma E - (\delta + \mu)I - \frac{\gamma I}{1 + bI} \right) \Delta t, \\
\mathbb{E}[R(t + \Delta t) - R(t)|X_t = x] &\approx (\mu I - \delta R) \Delta t,
\end{aligned}$$

and

$$\begin{aligned}
\text{Var}[S(t + \Delta t) - S(t)|X_t = x] &\approx \sigma_1^2 S^2(t) \Delta t, \\
\text{Var}[E(t + \Delta t) - E(t)|X_t = x] &\approx \sigma_2^2 E^2(t) \Delta t, \\
\text{Var}[I(t + \Delta t) - I(t)|X_t = x] &\approx \sigma_3^2 I^2(t) \Delta t, \\
\text{Var}[R(t + \Delta t) - R(t)|X_t = x] &\approx \sigma_4^2 R^2(t) \Delta t,
\end{aligned}$$

where  $\sigma_i^2 > 0$  are the intensities of white noises for  $i = 1, 2, 3, 4$ . Thus, we obtain the following stochastic epidemic model as follows:

$$\begin{aligned}
dS(t) &= \left( \Gamma - \delta S - \frac{\beta SI}{\phi(I)} + \frac{aE}{1 + kE} + \frac{\gamma I}{1 + bI} \right) dt + \sigma_1 S dB_1(t), \\
dE(t) &= \left( \frac{\beta SI}{\phi(I)} - (\delta + \sigma)E - \frac{aE}{1 + kE} \right) dt + \sigma_2 E dB_2(t), \\
dI(t) &= \left( \sigma E - (\delta + \mu)I - \frac{\gamma I}{1 + bI} \right) dt + \sigma_3 I dB_3(t), \\
dR(t) &= (\mu I - \delta R) dt + \sigma_4 R dB_4(t),
\end{aligned} \tag{1.3}$$

where  $B_i(t)$  are mutually independent standard Brownian motions with  $i = 1, 2, 3, 4$ .

**Remark 1.1.** We take  $a = 0$  and  $\gamma = 0$ , model (1.3) turns into model (6) in [9]. When  $\phi(I) = 1 + \alpha_1 S + \alpha_2 I$ ,  $a = 0$  and  $b = 0$ , model (1.3) becomes model (4) in [20]. When  $\phi(I) = 1 + \alpha I$ ,  $a = 0$  and  $b = 0$ , model (1.3) turns into model (1.4) in [44].

**Remark 1.2.** When  $a = 0$  and  $\gamma = 0$  in (1.2), the expressions of the basic reproduction number  $\mathcal{R}_0$  of model (6) in [9], model (4) in [20] and model (1.4) in [44] are same. That is,  $\mathcal{R}_0 = \Gamma\beta\sigma/[\delta(\delta + \sigma)(\delta + \mu)]$ . Moreover,  $\mathcal{R}_0 \leq 1$  and  $\mathcal{R}_0 > 1$  determine the extinction and the persistence of these three models therein. While, the values of  $a$  and  $\gamma$  of model (1.3) do not vanish, two indices  $\mathcal{R}_0$  and  $\mathcal{R}_0^s$  are given in the next investigations.

Noticing that the first three equations of model (1.1) are independent of the recovered, we therefore investigate the dynamics of the equivalent model (1.4) as follows:

$$\begin{aligned} dS(t) &= \left( \Gamma - \delta S - \frac{\beta SI}{\phi(I)} + \frac{aE}{1+kE} + \frac{\gamma I}{1+bI} \right) dt + \sigma_1 S dB_1(t), \\ dE(t) &= \left( \frac{\beta SI}{\phi(I)} - (\delta + \sigma)E - \frac{aE}{1+kE} \right) dt + \sigma_2 E dB_2(t), \\ dI(t) &= \left( \sigma E - (\delta + \mu)I - \frac{\gamma I}{1+bI} \right) dt + \sigma_3 I dB_3(t). \end{aligned} \quad (1.4)$$

Let  $(\Omega, \{\mathcal{F}_t\}_{t \geq 0}, \mathbb{P})$  be a complete probability space with a filtration  $\{\mathcal{F}_t\}_{t \geq 0}$  which is increasing and right continuous while  $\mathcal{F}_0$  contains all  $\mathbb{P}$ -null sets. Next, we will show a unique global positive solution to model (1.4). Then, the extinction and the persistence in the mean for model (1.4) will be considered under proper conditions in Section 2 and Section 3, respectively. The ergodic stationary distribution of model (1.4) is also verified in Section 4. Finally, several numerical simulations in Section 5 are carried out by two methods.

**Remark 1.3.** We take  $\phi(I) = 1$  and  $\sigma_1 = \sigma_2 = \sigma_3 = 0$ , model (1.4) turns into model (1.3) in [26]. Moreover, we take  $k = b = 0$ , model (1.4) turns into model (5.1) in [26]. The expressions of basic reproduction number of model (1.3) and model (5.1) in [26] are same with that of model (1.4) in this study.

## 2. Stochastic extinction

Before we discuss the dynamical behaviors of model (1.4), the unique global positive solution to model (1.4) should be checked firstly, the corresponding proof is similar to the proof in [27], so we only write down the following Theorem 2.1 without details.

**Theorem 2.1.** *For any given initial value  $(S(0), E(0), I(0))$  in  $\mathbb{R}_+^3$ , there is a unique solution  $(S(t), E(t), I(t))$  to model (1.4) on  $t \geq 0$  and the solution will remain in  $\mathbb{R}_+^3$  with probability one.*

**Proof.** We write down the lines and sentences as we did in the existence-and-uniqueness theorem in [27]. We just omit the details of proof hereby.  $\square$

Throughout this paper, we denote  $\langle x(t) \rangle = \frac{1}{t} \int_0^t x(s) ds$ .

**Theorem 2.2.** *Let  $(S(t), E(t), I(t))$  be the solution of model (1.4) with any initial value  $(S(0), E(0), I(0))$  in  $\mathbb{R}_+^3$ . If the basic reproduction number satisfies  $\mathcal{R}_0 < 1$ ,  $\mu > 0.5(\sigma_1^2 \vee \sigma_2^2 \vee \sigma_3^2)$  and*

$$\nu = (\gamma + \mu + \delta) \sqrt{\mathcal{R}_0} + \min\{a + \delta + \sigma, \gamma + \mu + \delta\} (\sqrt{\mathcal{R}_0} - 1) + \max\{a, \gamma\} - [2(\sigma_2^{-2} + \sigma_3^{-2})]^{-1} < 0,$$

*then, the infectious disease goes to extinction. That is,  $\lim_{t \rightarrow \infty} I(t) = 0$ .*

**Proof.** We define a  $C^2$ -function  $Z : \mathbb{R}_+^2 \rightarrow \mathbb{R}_+$  as follows:

$$Z(E, I) = \frac{1}{\gamma + \mu + \delta} \left( \frac{\sigma}{a + \delta + \sigma} E(t) + \sqrt{\mathcal{R}_0} I(t) \right) = \theta_1 E(t) + \theta_2 I(t).$$

By Itô's formula, we have

$$\begin{aligned} d \ln Z(E(t), I(t)) &= \frac{1}{Z} (\theta_1 dE + \theta_2 dI) - \frac{1}{2Z^2} [\theta_1^2 (dE)^2 + \theta_2^2 (dI)^2] \\ &= \mathcal{L}(\ln Z(E(t), I(t))) dt + \frac{1}{Z} [\theta_1 \sigma_2 E dB_2(t) + \theta_2 \sigma_3 I dB_3(t)]. \end{aligned}$$

Based on  $(a^2 + b^2)(c^2 + d^2) \geq (ac + bd)^2$ , for  $a > 0, b > 0, c > 0, d > 0$ , then, we get that

$$(\theta_1 E + \theta_2 I)^2 = \left( \theta_1 \sigma_2 E \frac{1}{\sigma_2} + \theta_2 \sigma_3 I \frac{1}{\sigma_3} \right)^2 \leq (\theta_1^2 \sigma_2^2 E^2 + \theta_2^2 \sigma_3^2 I^2) \left( \frac{1}{\sigma_2^2} + \frac{1}{\sigma_3^2} \right). \quad (2.1)$$

Therefore, from (1.4) and (2.1), we have

$$\begin{aligned} \mathcal{L} \ln Z(E(t), I(t)) &= \frac{1}{Z} \left( \theta_1 \frac{\beta S I}{\phi(I)} - \theta_1 \delta E - \theta_1 \sigma E - \theta_1 \frac{aE}{1 + kE} + \theta_2 \sigma E \right. \\ &\quad \left. - \theta_2 (\delta + \mu) I - \theta_2 \frac{\gamma I}{1 + bI} \right) - \frac{\theta_1^2 \sigma_2^2 E^2 + \theta_2^2 \sigma_3^2 I^2}{2(\theta_1 E + \theta_2 I)^2} := I_1 - I_2. \end{aligned}$$

Indeed, we estimate each item by the following approaches

$$\begin{aligned} I_1 &\leq \frac{1}{Z} \left\{ \theta_1 \beta S I - \theta_1 \delta E - \theta_1 \sigma E - \theta_1 aE + \theta_1 aE - \theta_1 \frac{aE}{1 + kE} + \theta_2 \sigma E - \theta_2 (\delta + \mu) I \right. \\ &\quad \left. - \theta_2 \gamma I + \theta_2 \gamma I - \theta_2 \frac{\gamma I}{1 + bI} \right\} \\ &\leq \frac{1}{Z} \left\{ \theta_1 \beta S I + \theta_1 \left[ \frac{\Gamma \beta I}{\delta} - (\delta + \sigma + a) E \right] + \theta_2 [\sigma E - (\delta + \mu + \gamma) I] + \theta_1 aE + \theta_2 \gamma I \right\} \\ &\leq \frac{\theta_1 \beta S}{\theta_2} + \frac{1}{Z} \left( \mathcal{R}_0 I - \frac{\sigma}{\gamma + \mu + \delta} E + \frac{\sqrt{\mathcal{R}_0} \sigma E}{\gamma + \mu + \delta} - \sqrt{\mathcal{R}_0} I \right) + \max\{a, \gamma\} \\ &= \frac{\theta_1 \beta S}{\theta_2} + \frac{1}{Z} (\sqrt{\mathcal{R}_0} - 1) [(a + \delta + \sigma) \theta_1 E + (\gamma + \mu + \delta) \theta_2 I] + \max\{a, \gamma\} \\ &\leq \frac{\theta_1 \beta S}{\theta_2} + \min\{a + \delta + \sigma, \gamma + \mu + \delta\} (\sqrt{\mathcal{R}_0} - 1) + \max\{a, \gamma\}, \end{aligned}$$

and  $I_2 \geq [2(\sigma_2^{-2} + \sigma_3^{-2})]^{-1}$ . Therefore, we derive

$$\begin{aligned} d \ln Z(E(t), I(t)) &\leq \left\{ \frac{\theta_1 \beta S}{\theta_2} + \min\{a + \delta + \sigma, \gamma + \mu + \delta\} (\sqrt{\mathcal{R}_0} - 1) + \max\{a, \gamma\} \right. \\ &\quad \left. - [2(\sigma_2^{-2} + \sigma_3^{-2})]^{-1} \right\} dt + \frac{\theta_1 \sigma_2}{Z} E dB_2(t) + \frac{\theta_2 \sigma_3}{Z} I dB_3(t). \end{aligned} \quad (2.2)$$

Taking integration on both sides of (2.2) and divided by  $t$ , one implies that

$$\begin{aligned} \frac{1}{t} \ln Z(E(t), I(t)) &\leq \frac{1}{t} \ln Z(E(0), I(0)) + \frac{1}{t} \int_0^t \frac{\theta_1 \beta}{\theta_2} S(s) ds \\ &\quad + \min\{a + \delta + \sigma, \gamma + \mu + \delta\}(\sqrt{\mathcal{R}_0} - 1) + \max\{a, \gamma\} \\ &\quad - [2(\sigma_2^{-2} + \sigma_3^{-2})]^{-1} + \frac{1}{t} M_1(t) + \frac{1}{t} M_2(t), \end{aligned} \quad (2.3)$$

where  $M_1(t) = \int_0^t \frac{\theta_1 \sigma_2 E(s)}{Z(s)} dB_2(s)$ ,  $M_2(t) = \int_0^t \frac{\theta_2 \sigma_3 I(s)}{Z(s)} dB_3(s)$  are local martingales, and their quadratic variations are  $\langle M_1(t), M_1(t) \rangle \leq \sigma_2^2 t$ ,  $\langle M_2(t), M_2(t) \rangle \leq \sigma_3^2 t$ . By Lemma 2 in [43], we derive that

$$\limsup_{t \rightarrow \infty} \frac{1}{t} M_i(t) = 0, \quad i = 1, 2 \quad \text{a.s.} \quad (2.4)$$

By (2.3) and (2.4), we take the upper limit on both sides, it then follows

$$\begin{aligned} \limsup_{t \rightarrow \infty} \frac{1}{t} \ln Z(E(t), I(t)) &\leq \frac{\theta_1 \beta \Gamma}{\theta_2 \delta} + \min\{a + \delta + \sigma, \gamma + \mu + \delta\}(\sqrt{\mathcal{R}_0} - 1) \\ &\quad + \max\{a, \gamma\} - [2(\sigma_2^{-2} + \sigma_3^{-2})]^{-1} := \nu \quad \text{a.s.} \end{aligned}$$

If  $\nu < 0$ , then we have  $\lim_{t \rightarrow \infty} I(t) = 0$  and  $\lim_{t \rightarrow \infty} E(t) = 0$ . The proof is complete.  $\square$

**Remark 2.1.** As claimed in Theorem 3.2 of [26] and Theorem 2.2 of this study, the basic reproduction number  $\mathcal{R}_0 < 1$  determines the extinction of model (1.3) of [26], also determines the extinction of model (1.4) of this study. We investigate the extinction time of the solution of model (1.4) with  $\phi(I) = 1$  in numerical simulation section. Further, we compare the differences of the extinction time for model (1.4) with  $\phi(I) = 1$  and model (1.3) of [26].

### 3. Stochastic persistence

The stochastic persistence of the infectious disease will be demonstrated in this section.

**Lemma 3.1.** *For any initial value  $(S(0), E(0), I(0)) \in \mathbb{R}_+^3$ , the solution  $(S(t), E(t), I(t))$  of model (1.4) has the following properties:*

$$\lim_{t \rightarrow \infty} \frac{1}{t} S(t) = 0, \quad \lim_{t \rightarrow \infty} \frac{1}{t} E(t) = 0, \quad \lim_{t \rightarrow \infty} \frac{1}{t} I(t) = 0 \quad \text{a.s.},$$

and

$$\limsup_{t \rightarrow \infty} \frac{1}{t} \ln S(t) \leq 0, \quad \limsup_{t \rightarrow \infty} \frac{1}{t} \ln E(t) \leq 0, \quad \limsup_{t \rightarrow \infty} \frac{1}{t} \ln I(t) \leq 0 \quad \text{a.s.}$$

Moreover, if  $\mu > 0.5(\sigma_1^2 \vee \sigma_2^2 \vee \sigma_3^2)$ , then

$$\lim_{t \rightarrow \infty} \frac{1}{t} \int_0^t S(s) dB_1(s) = 0, \quad \lim_{t \rightarrow \infty} \frac{1}{t} \int_0^t E(s) dB_2(s) = 0, \quad \lim_{t \rightarrow \infty} \frac{1}{t} \int_0^t I(s) dB_3(s) = 0 \quad \text{a.s.}$$

**Proof.** The proof is similar to the approaches used in [41, 42]. Therefore we make variable replacement that replace  $E(t)$  with  $I(t)$ , replace  $I(t)$  with  $V(t)$ , and  $S(t)$  remains unchanged, then we easily obtain the results of Lemma 3.1. We omit the details hereby.  $\square$

**Theorem 3.1.** Let  $(S(t), E(t), I(t))$  be a solution of model (1.4) with any initial value in  $\mathbb{R}_+^3$ . If

$$\mathcal{R}_0^s = \frac{\Gamma\beta\sigma}{(\delta + 0.5\sigma_1^2)(\delta + \sigma + a + 0.5\sigma_2^2)(\delta + \mu + \gamma + 0.5\sigma_3^2)} > \phi(\Gamma\delta^{-1}) > 1,$$

then, model (1.4) satisfies

$$\liminf_{t \rightarrow \infty} \langle I \rangle_t \geq \frac{1}{h} (\mathcal{R}_0^s - \phi(\Gamma\delta^{-1})) > 0, \quad h = \frac{\beta}{\delta + 0.5\sigma_1^2} \mathcal{R}_0^s.$$

In other words, the infectious disease will prevail in the long run.

**Proof.** Define  $Z_1 = -c_1 \ln S - c_2 \ln E - c_3 \ln I$ , where  $c_1, c_2, c_3$  are positive constants determined later. By applying Itô's formula, which gives that

$$\begin{aligned} \mathcal{L}Z_1(t) &= -\frac{c_1\Gamma}{S} + c_1\delta + \frac{c_1\beta I}{\phi(I)} - \frac{c_1aE}{(1+kE)S} - \frac{c_1\gamma I}{(1+bI)S} - \frac{c_2\beta SI}{E\phi(I)} + c_2(\delta + \sigma) \\ &\quad + \frac{ac_2}{1+kE} - \frac{c_3\sigma E}{I} + c_3\delta + c_3\mu + \frac{c_3\gamma}{1+bI} + 0.5c_1\sigma_1^2 + 0.5c_2\sigma_2^2 + 0.5c_3\sigma_3^2 \\ &< -\frac{c_1\Gamma}{S} - \frac{c_2\beta SI}{E\phi(I)} - \frac{c_3\sigma E}{I} - \phi(I) + \phi(I) + c_1\delta + c_1\beta I \\ &\quad + c_2\delta + c_2\sigma + ac_2 + c_3\delta + c_3\mu + c_3\gamma + 0.5c_1\sigma_1^2 + 0.5c_2\sigma_2^2 + 0.5c_3\sigma_3^2 \\ &\leq -4(c_1c_2c_3\Gamma\beta\sigma)^{\frac{1}{4}} + \phi(I) + c_1(\delta + 0.5\sigma_1^2) + c_1\beta I \\ &\quad + c_2(\delta + \sigma + a + 0.5\sigma_2^2) + c_3(\delta + \mu + \gamma + 0.5\sigma_3^2). \end{aligned}$$

Let

$$c_1 = \frac{\mathcal{R}_0^s}{\delta + 0.5\sigma_1^2}, \quad c_2 = \frac{\mathcal{R}_0^s}{\delta + \sigma + a + 0.5\sigma_2^2}, \quad c_3 = \frac{\mathcal{R}_0^s}{\delta + \mu + \gamma + 0.5\sigma_3^2}.$$

Then  $\mathcal{L}Z_1(t) \leq -\mathcal{R}_0^s + \phi(I) + hI$ ,  $h = c_1\beta$ , we thus derive that

$$dZ_1(t) \leq (-\mathcal{R}_0^s + \phi(I) + hI)dt - c_1\sigma_1 dB_1(t) - c_2\sigma_2 dB_2(t) - c_3\sigma_3 dB_3(t). \quad (3.1)$$

By Lemma 2.1,  $M_3(t) = \int_0^t c_1\sigma_1 dB_1(s) + \int_0^t c_2\sigma_2 dB_2(s) + \int_0^t c_3\sigma_3 dB_3(s)$  is a local martingale, and satisfies  $\lim_{t \rightarrow \infty} \frac{1}{t} M_3(t) = 0$ . Consequently, by (3.1), the integration implies that

$$\begin{aligned} \liminf_{t \rightarrow \infty} h \langle I \rangle_t &\geq \mathcal{R}_0^s - \limsup_{t \rightarrow \infty} \langle \phi(I) \rangle_t + \liminf_{t \rightarrow \infty} \frac{1}{t} Z_1(t) - \limsup_{t \rightarrow \infty} \frac{1}{t} Z_1(0) + \liminf_{t \rightarrow \infty} \frac{1}{t} M_3(t) \\ &\geq \mathcal{R}_0^s - \phi(\Gamma\delta^{-1}) > 0. \end{aligned}$$

The proof is complete.  $\square$



**Remark 3.1.** Let  $\sigma_1 = \sigma_2 = \sigma_3 = 0$ . Then  $\mathcal{R}_0^s$  degenerates  $\mathcal{R}_0$  as demonstrated in (1.2).

## 4. Existence of stationary distribution

In this section, the existence of an ergodic stationary distribution will be proved and sufficient conditions for the stationary will be established.

**Theorem 4.1.** *Let  $(S(0), E(0), I(0)) \in \mathbb{R}_+^3$  be any positive initial value, If  $\mathcal{R}_0^s > \phi(\Gamma\delta^{-1}) > 1$ , then, there exists a stationary distribution  $\mu(\cdot)$  for model (1.4), which is ergodic.*

**Proof.** The diffusion matrix of model (1.4) is given by  $\tilde{B} = \text{diag}\{\sigma_1^2 S^2, \sigma_2^2 E^2, \sigma_3^2 I^2\}$ . Meanwhile, we select  $L = \min_{(S,E,I) \in D_m \subset \mathbb{R}_+^3} \{\sigma_1^2 S^2, \sigma_2^2 E^2, \sigma_3^2 I^2\}$ . We get

$$\begin{aligned} \sum_{i,j=1}^3 a_{ij}(S, E, I) \xi_i \xi_j &= (\xi_1, \xi_2, \xi_3) \tilde{B} (\xi_1, \xi_2, \xi_3)^T \\ &= \sigma_1^2 S^2 \xi_1^2 + \sigma_2^2 E^2 \xi_2^2 + \sigma_3^2 I^2 \xi_3^2 \geq L \|\xi\|^2, \end{aligned}$$

for any  $(S, E, I) \in D_m$ ,  $\xi = (\xi_1, \xi_2, \xi_3) \in \mathbb{R}_+^3$ , where  $m > 1$  is a sufficiently large integer and  $D_m = [\frac{1}{m}, m] \times [\frac{1}{m}, m] \times [\frac{1}{m}, m]$ . Consequently, we take  $l$ -dimensional Euclidean space  $E_l = \mathbb{R}_+^3$  and  $U = D_m$ . That is, condition (A1) of [45] holds. For  $M > 0$  and a sufficiently small constant  $n > 0$ , we construct a nonnegative  $C^2$ -function  $\tilde{W} : \mathbb{R}_+^3 \rightarrow \mathbb{R}$  as follows

$$\tilde{W}(S, E, I) = M(-c_1 \ln S - c_2 \ln E - c_3 \ln I) - \ln S - \ln E + \frac{1}{n+1}(S + E + I)^{n+1}.$$

It is easy to check that  $\liminf_{m \rightarrow \infty, (S,E,I) \in \mathbb{R}_+^3 \setminus D_m} \tilde{W}(S, E, I) = +\infty$ . Besides,  $\tilde{W}(S, E, I)$  is a continuous function, and there is a minimum point  $P^*(S^*, E^*, I^*)$  of the function  $\tilde{W}(S, E, I)$  in the interior of  $\mathbb{R}_+^3$ . Then a nonnegative  $C^2$ -function  $\bar{W}$  is constructed as follows:

$$\bar{W}(S, E, I) = \tilde{W}(S, E, I) - \tilde{W}(S^*, E^*, I^*) = MZ_1 + Z_2 + Z_3 + Z_4 - \tilde{W}(S^*, E^*, I^*),$$

where  $Z_1$  is presented above, and define  $Z_2 = -\ln S$ ,  $Z_3 = -\ln E$ ,  $Z_4 = \frac{1}{n+1}(S + E + I)^{n+1}$ . Next, we choose a positive constant  $M$  such that the following conditions hold

$$\eta = \delta - 0.5n(\sigma_1^2 \vee \sigma_2^2 \vee \sigma_3^2) > 0,$$

$$\Xi(S, E, I) := 3M\lambda + 2\delta + \sigma + a + 0.5(\sigma_1^2 + \sigma_2^2) + B - 0.5\eta(S^{n+1} + E^{n+1} + I^{n+1}) \leq -2,$$

where

$$\lambda = \mathcal{R}_0^s, \quad B = \sup_{(S,E,I) \in \mathbb{R}_+^3} \{\Gamma(S + E + I)^n - 0.5\eta(S^{n+1} + E^{n+1} + I^{n+1})\}.$$

According to the similar discussions as shown in Theorem 3.1, we re-estimate  $Z_1$  here

$$\begin{aligned}\mathcal{L}Z_1(t) &< -\frac{c_1\Gamma}{S} - \frac{c_2\beta SI}{E\phi(I)} - \frac{c_3\sigma E}{I} + c_1\delta + c_1\beta I + c_2\delta + c_2\sigma + ac_2 \\ &\quad + c_3\delta + c_3\mu + c_3\gamma + 0.5(c_1\sigma_1^2 + c_2\sigma_2^2 + c_3\sigma_3^2) \\ &\leq -3\left(\frac{c_1c_2c_3\Gamma\beta\sigma}{\phi(I)}\right)^{\frac{1}{3}} + c_1(\delta + 0.5\sigma_1^2) + c_1\beta I \\ &\quad + c_2(\delta + \sigma + a + 0.5\sigma_2^2) + c_3(\delta + \mu + \gamma + 0.5\sigma_3^2),\end{aligned}$$

substituting  $c_1, c_2, c_3$  into the above expression, which gives the simplified form

$$\mathcal{L}Z_1(t) < -3\lambda\left(\frac{\lambda}{\phi(I)}\right)^{\frac{1}{3}} + 3\lambda + \frac{\beta\lambda}{\delta + 0.5\sigma_1^2}I.$$

By the same approaches, we get

$$\mathcal{L}Z_2 = -\frac{\Gamma}{S} + \delta + \frac{\beta I}{\phi(I)} - \frac{aE}{S(1+kE)} - \frac{\gamma I}{S(1+bI)} + \frac{\sigma_1^2}{2} < -\frac{\Gamma}{S} + \delta + \beta I + \frac{\sigma_1^2}{2},$$

$$\mathcal{L}Z_3 = -\frac{\beta SI}{E\phi(I)} + \delta + \sigma + \frac{a}{1+kE} + \frac{\sigma_2^2}{2} < -\frac{\beta SI}{E\phi(I)} + \delta + \sigma + a + \frac{\sigma_2^2}{2},$$

and

$$\begin{aligned}\mathcal{L}Z_4 &= (S + E + I)^n [\Gamma - \delta(S + E + I) - \mu I] + \frac{n}{2}(S + E + I)^{n-1}(\sigma_1^2 S^2 + \sigma_2^2 E^2 + \sigma_3^2 I^2) \\ &< \Gamma(S + E + I)^n - \left[\delta - \frac{n}{2}(\sigma_1^2 \vee \sigma_2^2 \vee \sigma_3^2)\right](S + E + I)^{n+1} \\ &\leq \Gamma(S + E + I)^n - \eta(S^{n+1} + E^{n+1} + I^{n+1}) < B - \frac{\eta}{2}(S^{n+1} + E^{n+1} + I^{n+1}).\end{aligned}$$

Therefore

$$\mathcal{L}\widetilde{W} \leq -3M\lambda\left(\frac{\lambda}{\phi(I)}\right)^{\frac{1}{3}} + \left(\frac{M\beta\lambda}{\delta + 0.5\sigma_1^2} + \beta\right)I - \frac{\Gamma}{S} - \frac{\beta SI}{E\phi(I)} + \Xi(S, E, I).$$

Next, we construct the following bounded closed set

$$D = \left\{ (S, E, I) \in \mathbb{R}_+^3 : \varepsilon_1 \leq S \leq \frac{1}{\varepsilon_1}, \varepsilon_2 \leq E \leq \frac{1}{\varepsilon_2}, \varepsilon_3 \leq I \leq \frac{1}{\varepsilon_3} \right\}$$

such that condition (A2) of [45] is valid, where  $\varepsilon_i > 0$  ( $i = 1, 2, 3$ ) are sufficiently small constants satisfying the expressions (4.1)–(4.6) as follows:

$$-\frac{\Gamma}{\varepsilon_1} + Q \leq -1, \quad (4.1)$$

$$-3M\lambda\left(\frac{\lambda}{\phi(\varepsilon_3)}\right)^{\frac{1}{3}} + \left(\frac{M\beta\lambda}{\delta + 0.5\sigma_1^2} + \beta\right)\varepsilon_3 + T \leq -1, \quad (4.2)$$

$$-\frac{\beta\varepsilon_1\varepsilon_3}{\varepsilon_2\phi(\varepsilon_3)} + Q \leq -1, \quad (4.3)$$

$$-\frac{\eta}{4\varepsilon_1^{n+1}} + U \leq -1, \quad (4.4)$$

$$-\frac{\eta}{4\varepsilon_3^{n+1}} + Y \leq -1, \quad (4.5)$$

$$-\frac{\eta}{4\varepsilon_2^{n+1}} + G \leq -1, \quad (4.6)$$

where

$$\begin{aligned} f(I) &= 3M\lambda + \left( \frac{M\beta\lambda}{\delta + 0.5\sigma_1^2} + \beta \right) I + 2\delta + \sigma + a + \frac{\sigma_1^2 + \sigma_2^2}{2} + B, \\ Q &= \sup_{(S,E,I) \in \mathbb{R}_+^3} \left\{ f(I) - \frac{\eta}{2}(S^{n+1} + E^{n+1} + I^{n+1}) \right\}, \quad T = \sup_{(S,E,I) \in \mathbb{R}_+^3} \left\{ \Xi(S, E, I) \right\}, \\ U &= \sup_{(S,E,I) \in \mathbb{R}_+^3} \left\{ f(I) - \frac{\eta}{4}S^{n+1} - \frac{\eta}{2}(E^{n+1} + I^{n+1}) \right\}, \\ Y &= \sup_{(S,E,I) \in \mathbb{R}_+^3} \left\{ f(I) - \frac{\eta}{4}I^{n+1} - \frac{\eta}{2}(S^{n+1} + E^{n+1}) \right\}, \\ G &= \sup_{(S,E,I) \in \mathbb{R}_+^3} \left\{ f(I) - \frac{\eta}{4}E^{n+1} - \frac{\eta}{2}(S^{n+1} + I^{n+1}) \right\}. \end{aligned}$$

For convenience, we divide  $\mathbb{R}_+^3 \setminus D$  into six domains:

$$\begin{aligned} D_1 &= \{(S, E, I) \in \mathbb{R}_+^3 : 0 < S < \varepsilon_1\}, & D_2 &= \{(S, E, I) \in \mathbb{R}_+^3 : 0 < I < \varepsilon_3\}, \\ D_3 &= \{(S, E, I) \in \mathbb{R}_+^3 : S \geq \varepsilon_1, 0 < E < \varepsilon_2, I \geq \varepsilon_3\}, & D_4 &= \left\{ (S, E, I) \in \mathbb{R}_+^3 : S > \frac{1}{\varepsilon_1} \right\}, \\ D_5 &= \left\{ (S, E, I) \in \mathbb{R}_+^3 : I > \frac{1}{\varepsilon_3} \right\}, & D_6 &= \left\{ (S, E, I) \in \mathbb{R}_+^3 : E > \frac{1}{\varepsilon_2} \right\}. \end{aligned}$$

Clearly,  $D^c = D_1 \cup D_2 \cup \dots \cup D_6$ . Thus, we only need to prove  $\mathcal{L}\widetilde{W}(S, E, I) \leq -1$  on  $D^c$ .

**Case 1.** When  $(S, E, I) \in D_1$ , by (4.1), we get that

$$\mathcal{L}\widetilde{W} < -\frac{\Gamma}{S} + \left( \frac{M\beta\lambda}{\delta + 0.5\sigma_1^2} + \beta \right) I + \Xi(S, E, I) \leq -\frac{\Gamma}{\varepsilon_1} + Q \leq -1.$$

**Case 2.** When  $(S, E, I) \in D_2$ , by (4.2), we have that

$$\mathcal{L}\widetilde{W} < -3M\lambda \left( \frac{\lambda}{\phi(\varepsilon_3)} \right)^{\frac{1}{3}} + \left( \frac{M\beta\lambda}{\delta + 0.5\sigma_1^2} + \beta \right) I + \Xi(S, E, I) \leq -1.$$

**Case 3.** When  $(S, E, I) \in D_3$ , by (4.3), we have that

$$\mathcal{L}\widetilde{W} < \left( \frac{M\beta\lambda}{\delta + 0.5\sigma_1^2} + \beta \right) I - \frac{\beta SI}{E\phi(I)} + \Xi(S, E, I) \leq -\frac{\beta\varepsilon_1\varepsilon_3}{\varepsilon_2\phi(\varepsilon_3)} + Q \leq -1.$$

**Case 4.** When  $(S, E, I) \in D_4$ , by (4.4), we get that

$$\mathcal{L}\widetilde{W} < -\frac{\eta}{4}S^{n+1} + f(I) - \frac{\eta}{4}S^{n+1} - \frac{\eta}{2}(E^{n+1} + I^{n+1}) \leq -\frac{\eta}{4\varepsilon_1^{n+1}} + U \leq -1.$$

**Case 5.** When  $(S, E, I) \in D_5$ , by (4.5), we get that

$$\mathcal{L}\widetilde{W} < -\frac{\eta}{4}I^{n+1} + f(I) - \frac{\eta}{4}I^{n+1} - \frac{\eta}{2}(S^{n+1} + E^{n+1}) \leq -\frac{\eta}{4\varepsilon_3^{n+1}} + Y \leq -1.$$

**Case 6.** When  $(S, E, I) \in D_6$ , by (4.6), we get that

$$\mathcal{L}\widetilde{W} < -\frac{\eta}{4}E^{n+1} + f(I) - \frac{\eta}{4}E^{n+1} - \frac{\eta}{2}(S^{n+1} + I^{n+1}) \leq -\frac{\eta}{4\varepsilon_2^{n+1}} + G \leq -1.$$

The proof is complete.  $\square$

## 5. Examples with numerical simulations

The numerical simulations are demonstrated by two examples in this section. The comparison investigations of Milstein's higher order method (MHOM in [46]) and positivity preserving truncated Euler-Maruyama method (PPTM in [47]) are operated in the first example. A case study is extensively discussed on Fuzhou COVID-19 epidemic of 2022 as the second example. The parameter values of the simulations in Example 5.1, Example 5.2 and Example 5.3 are provided in Table 1.

**Table 1.** Parameter values of the simulations in Example 5.1, Example 5.2 and Example 5.3.

Group	$\Gamma$	$\beta$	$\delta$	$a$	$\gamma$	$\sigma$
(I)	0.20	0.01	0.04	0.15	0.10	0.08
(II)	0.65	0.70	0.15	0.25	0.20	0.25
(III)	488.39	$1.99 \times 10^{-6}$	$1.67 \times 10^{-5}$	0.22	0.18	0.25
Group	$\sigma_1$	$\sigma_2$	$\sigma_3$	$k$	$b$	$\phi(I)$
(I)	0.0080	0.006	0.03	1	1	$1 + 0.25I$
(II)	0.0100	0.006	0.02	1	1	$1 + 0.25I$
(III)	0.0005	0	0	1/70	1/360	$1 + 0.25I$
Group	$\mu$	$\Delta t$	$S(0)$	$E(0)$	$I(0)$	
(I)	0.20	0.001	0.8	0.7	0.6	
(II)	0.25	0.001	0.8	0.7	0.6	
(III)	0.03	0.001	8,291,268	350	20	

<sup>1</sup> For Group (III), the main parameters of model (1.4) are computed as  $\Gamma = 0.0215 \times 8291268/365 = 488.39$ ,  $\delta = 0.0061/365 = 1.67 \times 10^{-5}$ , where 0.0215 is yearly growth rate and 0.0061 is yearly natural death rate by Fujian Bureau of Statistics in [48]. By the idea of Least Square,  $\beta = 1.99 \times 10^{-6}$  is obtained. By surveillance data from Fujian CDC,  $\mu = 0.03$  is derived. The initial values  $S(0)$ ,  $E(0)$ ,  $I(0)$  are from the reported data released by Fujian Provincial Health Commission in [49].

### 5.1. Two types of discretization equations

(i) Discretization equation with MHOM. With MHOM in [46], model (1.4) is written as follows:

$$\begin{aligned}
S(t_{k+1}) &= S(t_k) + \left[ \Gamma - \delta S(t_k) - \frac{\beta S(t_k)I(t_k)}{\phi(I(t_k))} + \frac{aE(t_k)}{1+kE(t_k)} + \frac{\gamma I(t_k)}{1+bI(t_k)} \right] \Delta t \\
&\quad + \sigma_1 S(t_k) \xi_1 \sqrt{\Delta t} + \frac{\sigma_1^2}{2} S(t_k) (\xi_1^2 - 1) \Delta t, \\
E(t_{k+1}) &= E(t_k) + \left[ \frac{\beta S(t_k)I(t_k)}{\phi(I(t_k))} - \delta E(t_k) - \sigma E(t_k) - \frac{aE(t_k)}{1+kE(t_k)} \right] \Delta t \\
&\quad + \sigma_2 E(t_k) \xi_2 \sqrt{\Delta t} + \frac{\sigma_2^2}{2} E(t_k) (\xi_2^2 - 1) \Delta t, \\
I(t_{k+1}) &= I(t_k) + \left[ \sigma E(t_k) - (\delta + \mu)I(t_k) - \frac{\gamma I(t_k)}{1+bI(t_k)} \right] \Delta t \\
&\quad + \sigma_3 I(t_k) \xi_3 \sqrt{\Delta t} + \frac{\sigma_3^2}{2} I(t_k) (\xi_3^2 - 1) \Delta t,
\end{aligned}$$

where  $\sigma_i^2 > 0$  ( $i = 1, 2, 3$ ) are the intensities of the white noises, the time increment  $\Delta t$  is positive, and  $\xi_i$  ( $i = 1, 2, 3$ ) are independent Gaussian random variables which follow the normal distribution  $\mathcal{N}(0, 1)$  for  $k = 0, 1, 2, \dots, n$ .

**(ii) Discretization equation with PPTEM.** By PPTEM in [47], model (1.4) is written below:

$$\begin{aligned}
S(t_{k+1}) &= S(t_k) + (\Gamma + f_{11} + f_{12})\Delta t + g_1 \sqrt{\Delta t}, \\
E(t_{k+1}) &= E(t_k) + (f_{21} + f_{22})\Delta t + g_2 \sqrt{\Delta t}, \\
I(t_{k+1}) &= I(t_k) + (f_{31} + f_{32})\Delta t + g_3 \sqrt{\Delta t},
\end{aligned}$$

where

$$\begin{aligned}
f_{11} &= -\delta \hat{\pi}_0(S(t_k)), \quad f_{12} = -\frac{\beta \hat{\pi}_0(S(t_k)I(t_k))}{\phi(\hat{\pi}_0(I(t_k)))} + \frac{a \hat{\pi}_0(E(t_k))}{1+k \hat{\pi}_0(E(t_k))} + \frac{\gamma \hat{\pi}_0(I(t_k))}{1+b \hat{\pi}_0(I(t_k))}, \\
f_{21} &= -(\delta + \sigma) \hat{\pi}_0(E(t_k)), \quad f_{22} = \frac{\beta \hat{\pi}_0(S(t_k)I(t_k))}{\phi(\hat{\pi}_0(I(t_k)))} - \frac{a \hat{\pi}_0(E(t_k))}{1+k \hat{\pi}_0(E(t_k))}, \\
f_{31} &= \sigma \hat{\pi}_0(E(t_k)) - (\delta + \mu) \hat{\pi}_0(I(t_k)), \quad f_{32} = -\frac{\gamma \hat{\pi}_0(I(t_k))}{1+b \hat{\pi}_0(I(t_k))},
\end{aligned}$$


$$g_1 = \sigma_1 \hat{\pi}_0(S(t_k)) r_{1,k}, \quad g_2 = \sigma_2 \hat{\pi}_0(E(t_k)) r_{2,k}, \quad g_3 = \sigma_3 \hat{\pi}_0(I(t_k)) r_{3,k}, \quad \hat{\pi}_0(u) = \max\{0, u\},$$

and  $r_{i,k}$  ( $i = 1, 2, 3, k = 0, 1, 2, 3, \dots$ ) are independent random variables with the normal distribution  $\mathcal{N}(0, 1)$ .


### 5.2. Numerical simulations of stochastic extinction and persistence of model (1.4)

**Example 5.1.** (Stochastic extinction) We choose the parameter values in Group (I) in Table 1, by conditions of Theorem 2.2, then, model (1.4) admits a disease-free

equilibrium point  $P_0(5, 0, 0)$ , and  $\mathcal{R}_0 = 0.0435 < 1$ ,  $\mu = 0.2 > 0.5(\sigma_1^2 \vee \sigma_2^2 \vee \sigma_3^2) = 0.00005$ . The corresponding simulations are demonstrated by MHOM and PPTEM in Figure 1 as  $n = 30000$ . Moreover, the extinction time for model (1.4) and model (1.4) with  $\sigma_1 = \sigma_2 = \sigma_3 = 0$  are compared, from which we conclude that the extinction time for the exposed and the infected of model (1.4) becomes a bit later as presented in Figure 2. We also notice that when the values of  $b$  and  $k$  turn out to be smaller, the extinction time that the infected individuals spent gets earlier as shown in Figure 3. When the larger fluctuations  $\sigma_1 = 0.1$ ,  $\sigma_2 = 0.1$ ,  $\sigma_3 = 0.2$  and  $n = 20000$  are given, the corresponding simulations show that the disease reaches extinction faster in Figure 4.



**Figure 1.** Stochastic extinction of  $E$  and  $I$  under Group (I) of model (1.4) with MHOM and PPTEM.




**Figure 2.** Comparisons of the extinctions of  $E$  and  $I$  for deterministic model and stochastic model under PPTEM.


**Example 5.2.** (Stochastic persistence) We use the parameter values in Group (II) in Table 1, then, model (1.4) admits an endemic equilibrium point  $P^*(S^*, E^*, I^*) = (1.6884, 1.1348, 0.5228)$  by PPTEM. Moreover, we have  $\mathcal{R}_0^s = 2.1652 > 1$ , and  $\liminf_{t \rightarrow \infty} \langle I \rangle_t \geq 0.3818$ . Therefore, we take  $n = 100000$ , model (1.4) admits a stationary distribution presented by Theorem 3.1 and Theorem 4.1, and the stochastic persistence of model (1.4) is demonstrated in Figure 5.

### 5.3. Numerical simulations of Fuzhou COVID-19 epidemic in 2022

**Example 5.3.** (A case study of Fuzhou COVID-19 epidemic). Since Chinese government issued Twenty Measures on November 11 of 2022, and New Ten Measures on December 7 of 2022, the tendency of Fuzhou COVID-19 epidemic fluctuated during the period from November 22 to December 12 of 2022. We take the parameter values of Group (III) in Table 1 and the awareness delay is set as 6 days by [50–52].



**Figure 3.** Stochastic extinctions of  $E$  and  $I$  to model (1.4) with PPTEM. Top for changes of  $k$ , bottom for changes of  $b$ .




**Figure 4.** Stochastic extinction of  $E$  and  $I$  to model (1.4) under MHOM and PPTEM with larger fluctuations  $\sigma_1 = 0.1$ ,  $\sigma_2 = 0.1$ ,  $\sigma_3 = 0.2$ .

The numerical simulations are operated by PPTEM based on the surveillance data from Fujian Provincial Center for Disease Control and Prevention (short for, Fujian CDC) in Figure 6.


The results of numerical simulations reveal the peak of  $E$  on the 10th day with 622 cases, and the peak of  $I$  on the 18th day with 620 cases as shown in Figure 7. Meanwhile, the decreasing of  $k$  implies the increasing of the innate immunity, the decreasing of  $b$  implies the increasing of the treatment availability, further, the time that both  $E$  and  $I$  approach zero reduces in Figure 8, which are consistent with the results in Figure 3.

## 6. Conclusion

The innate immunity of the individuals was usually regarded as the protection abilities during the progress that pathogen or virus invaded the hosts. So, the innate immunity played vital roles when controlling of the infectious diseases. We considered the innate immunity in the form of Holling type II functional response in this paper, instead of linear form, to establish a nonlinear stochastic epidemic model with innate immunity. Then, the stochastic extinction and stochastic persistence under moderate conditions, the existence of stationary distribution were



**Figure 5.** Left for histogram of  $S$ ,  $E$ , and  $I$  to model (1.4), right for stochastic persistence of  $S$ ,  $E$  and  $I$  to model (1.4) with MHOM and PPTEM.




**Figure 6.** Cumulative number of infection cases for Fuzhou COVID-19 epidemic led by SARS-CoV-2 Omicron BA.5.2 from October 23 to December 22 of 2022.


extensively discussed. Therefore, the main numerical simulations by two methods were performed to demonstrate the differences therein.

We showed that model (1.4) admitted a unique global positive solution with the positive initial value. Further, we derived that the infectious disease approached extinction when  $\mathcal{R}_0 < 1$ ,  $\nu < 0$  and  $2\mu > \sigma_1^2 \vee \sigma_2^2 \vee \sigma_3^2$  were valid as shown in Figure 1. Meanwhile, the persistence in the mean and the existence of ergodic stationary distribution to model (1.4) were obtained when  $\mathcal{R}_0^s > \phi(\Gamma\delta^{-1})$  held. The results showed that the parameters  $a$  and  $k$  of innate immunity were involved into the sufficient conditions of the extinction, persistence in the mean and ergodic stationary distribution to model (1.4). We explored that the increasing values of  $k$  and  $b$  made the





**Figure 7.** Numerical simulations of  $E$ ,  $I$ ,  $g(E)$  and  $h(I)$  for 300 days to Fuzhou epidemic by using model (1.4) with  $\sigma_1 = 0.0005, \sigma_2 = 0, \sigma_3 = 0$ .



**Figure 8.** Stochastic extinctions of  $E$  and  $I$  to Fuzhou epidemic by using model (1.4) with  $\sigma_1 = 0.0005, \sigma_2 = 0, \sigma_3 = 0$ . Top for changes of  $b$ , bottom for changes of  $k$ .

time that the exposed and the infected approached zero earlier as demonstrated in Figure 3 and Figure 8. That was to say, the individuals with low innate immunity in the population took high risks against infection, these individuals should be treated promptly by medical agents. The main results of this study improved the ones in model (6) of [9], model (4) of [20] and model (1.4) of [44] for the case of  $a = 0$  and  $\gamma = 0$ , which provided a new biological perspective to the respiratory infectious diseases.

Moreover, we were motivated by results of two-group SEIR model in [53], intended to propose a multi-group stochastic SEIR with time delay in the next investigation.

## Acknowledgements

We declared that all authors conceived of the study and carried out the proof. All authors of this paper read and approved the final manuscript.

## References

[1] W. Kermack, A. McKendric, *A contribution to the mathematical theory of epidemics*, Proc. Roy. Soc. Ser. A, 1927, 115, 700–721.

- [2] S. Ruan, W. Wang, *Dynamical behavior of an epidemic model with a nonlinear incidence rate*, J. Differ. Equ., 2003, 188, 135–163.
- [3] W. Wang, *Global behavior of an seirs epidemic model with time delays*, Appl. Math. Lett., 2002, 15, 423–428.
- [4] X. Fan, Z. Wang, *Stability analysis of an SEIR epidemic model with stochastic perturbation and numerical simulation*, Int. J. Nonlinear Sci. Numer. Simul., 2013, 14(2), 113–121.
- [5] F. Wei, F. Chen, *Stochastic permanence of an SIQS epidemic model with saturated incidence and independent random perturbations*, Physica A, 2016, 453(1), 99–107.
- [6] F. Wei, J. Liu, *Long-time behavior of a stochastic epidemic model with varying population size*, Physica A, 2017, 470, 146–153.
- [7] L. Chen, F. Wei, *Persistence and distribution of a stochastic susceptible-infected-recovered epidemic model with varying population size*, Physica A, 2017, 483, 386–397.
- [8] R. Lu, F. Wei, *Persistence and extinction for an age-structured stochastic SVIR epidemic model with generalized nonlinear incidence rate*, Physica A, 2019, 513, 572–587.
- [9] F. Wei, R. Xue, *Stability and extinction of SEIR epidemic models with generalized nonlinear incidence*, Math. Comput. Simul., 2020, 170, 1–15.
- [10] W. Wang, S. Ruan, *Bifurcation in an epidemic model with constant removal rate of the infectives*, J. Math. Anal. Appl., 2004, 291(2), 775–793.
- [11] W. Wang, *Backward bifurcation of an epidemic model with treatment*, Math. Biosci., 2006, 201, 58–71.
- [12] L. Zhou, M. Fan, *Dynamics of an SIR epidemic model with limited medical resources revisited*, Nonlinear Anal. Real World Appl., 2012, 13(1), 312–324.
- [13] G. Li, Z. Jin, *Global stability of an SEI epidemic model*, Chaos Solitons Fractals, 2004, 21(4), 925–931.
- [14] G. Li, Z. Jin, *Global stability of an SEI epidemic model with general contact rate*, Chaos Solitons Fractals, 2005, 23(3), 997–1004.
- [15] B. Mukhopadhyay, R. Bhattacharyya, *Analysis of a spatially extended nonlinear SEIS epidemic model with distinct incidence for exposed and infectives*, Nonlinear Anal. Real World Appl., 2008, 9(2), 585–598.
- [16] J. Zhang, Z. Ma, *Global dynamics of an SEIR epidemic models with saturating contract rate*, Math. Biosci., 2003, 185(1), 15–32.
- [17] M. Khan, Y. Khan, S. Lslam, *Complex dynamics of an SEIR epidemic models with saturated incidence rate and treatment*, Physica A, 2018, 493, 210–227.
- [18] A. Kaddar, A. Abta, T. Alaoui, *A comparison of delayed SIR and SEIR epidemic models*, Nonlinear Anal. Model. Control, 2011, 16(2), 181–190.
- [19] Z. Liu, *Dynamics of positive solutions to SIR and SEIR epidemic models with saturated incidence rates*, Nonlinear Anal. Real World Appl., 2013, 14(3), 1286–1299.
- [20] F. Liu, F. Wei, *An epidemic model with Beddington-DeAngelis functional response and environmental fluctuations*, Physica A, 2022, 597, 127321.

- [21] R. Lu, F. Wei, *Persistence and extinction for an age-structured stochastic SVIR epidemic model with generalized nonlinear incidence rate*, Physica A, 2019, 513, 572–587.
- [22] J. Lin, Z. Lu, G. Li, *MCPIP-1-mediated immunosuppression of neutrophils exacerbates acute bacterial peritonitis and liver injury*, J. Innate Immun., 2023, 15(1), 262–282.
- [23] X. Zhang, Z. Kang, D. Yin, et al., *Role of neutrophils in different stages of atherosclerosis*, Innate Immun., 2023, 29(6), 17534259231189195.
- [24] S. Mwalili, M. Kimathi, V. Ojiambo, et al., *SEIR model for COVID-19 dynamics incorporating the environment and social distancing*, BMC Res. Notes, 2020, 13(1), 1–5.
- [25] Y. Deng, M. Liu, *Analysis of a stochastic tumor-immune model with regime switching and impulsive perturbations*, Appl. Math. Model., 2020, 78, 482–504.
- [26] S. Jain, S. Kumar, *Dynamical analysis of SEIS model with nonlinear innate immunity and saturated treatment*, Eur. Phys. J. Plus, 2021, 136(9), 952.
- [27] Q. Liu, D. Jiang, N. Shi, et al., *Stationary distribution and extinction of a stochastic SIRS epidemic model with standard incidence*, Physica A, 2017, 469, 510–517.
- [28] Y. Zhang, *A remark on stationary distribution of a stochastic SIR epidemic model with double saturated rates*, Appl. Math. Lett., 2018, 76, 46–52.
- [29] J. Day, J. Rubin, Y. Vodovotz, et al., *A reduced mathematical model of the acute inflammatory response II. Capturing scenarios of repeated endotoxin administration*, J. Theor. Biol., 2006, 242(1), 237–256.
- [30] G. Gasteiger, A. Osualdo, D. Schubert, et al., *Cellular Innate Immunity: An old game with new players*, J. Innate Immun., 2017, 9(2), 111–125.
- [31] R. Kumar, G. Clermont, Y. Vodovotz, et al., *The dynamics of acute inflammation*, J. Theor. Biol., 2004, 230(2), 145–155.
- [32] A. Pigozzo, G. Macedo, R. Santos, et al., *On the computational modeling of the innate immune system*, BMC Bioinform., 2013, 14, S7.
- [33] A. Reynolds, J. Rubin, G. Clermont, et al., *A reduced mathematical model of the acute inflammatory response: I. Derivation of model and analysis of anti-inflammation*, Lab. Anim. Science, 1991, 41(3), 288–290.
- [34] Z. Shi, C. Wu, D. Arieih, et al., *Mathematical model of innate and adaptive immunity of sepsis: a modeling and simulation study of infectious disease*, BioMed Res. Int., 2015, 2015, 504259.
- [35] B. Su, W. Zhou, K. Dorman, et al., *Mathematical modelling of immune response in tissues*, Comput. Math. Methods. Med., 2009, 10(1), 9–38.
- [36] X. Wang, Y. Tao, X. Song, *Global stability of a virus dynamics model with Beddington-De Angelis incidence rate and CTL immune response*, Nonlinear Dyn., 2011, 66(4), 825–830.
- [37] H. Yang, J. Wei, *Analyzing global stability of a viral model with general incidence rate and cytotoxic T lymphocytes immune response*, Nonlinear Dyn., 2015, 82(1–2), 713–722.

- [38] O. Diekmann, J. Heesterbeek, J. Metz, *On the definition and the computation of the basic reproduction ratio  $\mathcal{R}_0$  in models for infectious diseases in heterogeneous populations*, J. Math. Biol., 1990, 28(4), 365–382.
- [39] O. Diekmann, J. Heesterbeek, M. Roberts, *The construction of next-generation matrices for compartmental epidemic models*, J. R. Soc. Interface, 2010, 7(47), 873–885.
- [40] V. Pauline, W. James, *A simple SIS epidemic model with a backward bifurcation*, J. Math. Biol., 2000, 40(6), 525–540.
- [41] Y. Zhao, D. Jiang, *Dynamics of stochastically perturbed SIS epidemic model with vaccination*, Abstr. Appl. Anal., 2013, 2013, 1–12.
- [42] Y. Zhao, D. Jiang, *The threshold of a stochastic SIS epidemic model with vaccination*, Appl. Math. Comput., 2014, 243, 718–727.
- [43] X. Mao, *Stochastic Differential Equations and Applications*, second ed., Chichester, Horwood Publishing, 2007.
- [44] Q. Yang, D. Jiang, N. Shi, et al., *The ergodicity and extinction of stochastically perturbed SIR and SEIR epidemic models with saturated incidence*, J. Math. Anal. Appl., 2012, 388(1), 248–271.
- [45] F. Wei, L. Chen, *Extinction and stationary distribution of an epidemic model with partial vaccination and nonlinear incidence rate*, Physica A, 2002, 545, 122852.
- [46] D. Higham, *An algorithmic introduction to numerical simulation of stochastic differential equations*, SIAM Rev., 2001, 43(3), 525–546.
- [47] X. Mao, F. Wei, T. Wiriyaikul, *Positivity preserving truncated Euler-Maruyama method for stochastic Lotka-Volterra competition model*, J. Comput. Appl. Math., 2021, 394, 113566.
- [48] *Fujian Statistical Yearbook, Fujian Provincial Bureau of Statistics*, 2022. Available from: <https://tjj.fujian.gov.cn/tongjijianjian/dz2022/index.htm>.
- [49] *Fujian Provincial Health Commission*, Available from: <https://wjw.fujian.gov.cn>.
- [50] S. Huang, F. Wei, Z. Peng, et al., *Assessment method of coronavirus disease 2019 outbreaks under normal prevention and control*, Dis. Surveill., 2020, 35(8), 679–686.
- [51] F. Wei, R. Zhou, Z. Jin, et al., *COVID-19 transmission driven by age-group mathematical model in Shijiazhuang City of China*, Infect. Dis. Model., 2023, 8, 1050–1062.
- [52] F. Wei, Z. Peng, Z. Jin, et al., *Study and prediction of the 2022 global monkey-pox epidemic*, J. Biosaf. Biosec., 2022, 4(2), 158–162.
- [53] M. Liu, C. Bai, K. Wang, *Asymptotic stability of a two-group stochastic SEIR model with infinite delays*, Commun. Nonlinear Sci. Numer. Simul., 2014, 19(10), 3444–3453.